Skip to main content

Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

Alexander Drilon, MD; Karen Reckamp, MD, MS; Lyudmila Bazhenova, MD; Anjali Saqi, MD, MBA

CME / ABIM MOC Released: 05/15/2023
Valid for credit through: 05/15/2024

Activity Overview
The use of molecular testing and biomarker-driven therapy has undergone marked growth and development for the management of non–small cell lung cancer (NSCLC) in recent years. As such, there is a critical need to provide education on how these tests work, emerging biomarkers (in particular, gene fusions), and the appropriate use of investigational therapies targeting current and emerging biomarkers to ultimately improve patients’ outcomes.

Medical Crossfire®, one of PER®’s signature educational formats, is a virtual program during which a panel of distinguished experts engages in spirited discussions and debates on a particular clinical topic. In this activity, 4 key thought leaders in pathology and medical oncology explore the latest data regarding current and emerging diagnostic and therapeutic strategies for patients with NSCLC that exhibits gene fusion.

Target Audience
These activities are intended for pathologists and other oncology health care professionals interested in the latest advances in the diagnosis, treatment, and management of NSCLC.

Acknowledgement of Commercial Support
This activity is supported by an educational grant from Lilly.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain biomarker testing strategies including comprehensive genomic profiling, to detect rarer mutations and rearrangements in advanced non–small cell lung cancer (NSCLC) settings
  • Determine approaches to practically integrate biomarker testing in community settings to identify oncogenic gene fusions among patients with NSCLC
  • Describe clinical trial evidence concerning the role of genotype-directed therapies in patients with NSCLC and oncogenic gene fusions
  • Assess residual challenges and gaps that preclude optimized testing and treatment for oncogenic fusion-positive NSCLC, including strategies or ongoing trials intended to address these unmet needs in the field

Continuing Medical Education

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.